Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Cardiology, Kaifeng Central Hospital, Kaifeng, China.
Am J Cardiol. 2020 May 15;125(10):1471-1478. doi: 10.1016/j.amjcard.2020.02.025. Epub 2020 Mar 5.
Thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI) is reported to improve myocardial reperfusion. However, the long-term prognostic implication of TA remains unclear. We aimed to investigate the influence of adjunctive TA on long-term outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing PPCI. All STEMI patients from China that included in the TOTAL trial who were ≥18 years old and referred for PPCI within the 12 hours after symptom onset between January 2011 and November 2012 were retrospectively analyzed. Patients were divided into 2 groups based on the use of TA or not. The primary efficacy outcomes were 5-year major adverse cardiac events, a composite of cardiovascular death, recurrent MI, cardiogenic shock, or heart failure hospitalization. The primary safety outcome was a 5-year stroke. A total of 563 patients were included. The incidence rate of major adverse cardiac events at 5 years in the TA group was similar to that in the PCI group (hazard ratio [HR] 0.70; 95% confidence interval [CI] 0.42 to 1.17). In addition, TA was significantly associated with a nearly sevenfold increased risk of stroke at 5 years compared with PCI alone (HR 7.32, 95% CI 1.33 to 40.31). Our propensity scoring match analyses suggested that patients with an occluded lesion might benefit from the TA (HR 0.24, 95% CI 0.08 to 0.70). In conclusion, TA is not associated with improved outcomes in patients with STEMI but may have an adverse impact on stroke. Patients with an occluded infarct-related artery could benefit from the TA.
血栓抽吸(TA)在经皮冠状动脉介入治疗(PPCI)中被报道可改善心肌再灌注。然而,TA 对长期预后的影响尚不清楚。我们旨在研究辅助 TA 对接受 PPCI 的 ST 段抬高型心肌梗死(STEMI)患者长期预后的影响。
回顾性分析了 2011 年 1 月至 2012 年 11 月期间发病 12 小时内接受 PPCI 的中国 TOTAL 试验中所有年龄≥18 岁的 STEMI 患者。根据是否使用 TA 将患者分为 2 组。主要疗效终点为 5 年主要不良心脏事件,包括心血管死亡、再发心肌梗死、心源性休克或心力衰竭住院的复合终点。主要安全性结局为 5 年卒。
共纳入 563 例患者。TA 组 5 年主要不良心脏事件发生率与 PCI 组相似(危险比[HR]0.70;95%置信区间[CI]0.42 至 1.17)。此外,与单独 PCI 相比,TA 与 5 年时卒中风险增加近 7 倍相关(HR 7.32,95%CI 1.33 至 40.31)。我们的倾向评分匹配分析表明,闭塞病变患者可能从 TA 中获益(HR 0.24,95%CI 0.08 至 0.70)。
总之,TA 与 STEMI 患者的改善结局无关,但可能对卒中产生不利影响。闭塞梗死相关动脉的患者可能从 TA 中获益。